Group 1 - The core viewpoint of the news highlights the recent stock performance and trading activity of Tai Long Pharmaceutical, showing a 2.13% increase in stock price to 6.70 CNY per share, with a total market capitalization of 3.845 billion CNY [1] - The company has seen a year-to-date stock price increase of 31.63%, but has experienced a decline of 2.33% over the last five trading days and 11.26% over the last twenty days [1] - Tai Long Pharmaceutical has been featured on the "Dragon and Tiger List" three times this year, with the most recent instance on December 10, where it recorded a net buy of -8.4516 million CNY [1] Group 2 - Tai Long Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The company's revenue composition includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of September 30, 2025, Tai Long Pharmaceutical reported a revenue of 1.187 billion CNY, a year-on-year decrease of 11.47%, and a net profit of 25.3255 million CNY, down 12.36% year-on-year [2] Group 3 - Tai Long Pharmaceutical has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.5307 million CNY distributed over the past three years [3] - As of September 30, 2025, the company had 40,400 shareholders, a decrease of 1.08% from the previous period, with an average of 14,190 circulating shares per shareholder, an increase of 1.09% [2][3] - Notable institutional holdings include Guangfa Pension Index A as the eighth largest shareholder with 2.9719 million shares, down by 264,000 shares, and Huatai-PineBridge CSI Traditional Chinese Medicine ETF as the ninth largest shareholder with 2.8616 million shares, marking a new entry [3]

南方财经12月30日电，天眼查App显示，近日，广东粤财中瀛新兴产业股权投资基金合伙企业（有限合伙）成立，执行事务合伙人为中银资本私募基金管理 （北京）有限公司、粤财中垠私募股权投资基金管理（广东）有限公司，出资额10亿人民币，经营范围为以私募基金从事股权投资、投资管理、资产管理等 活动，由超研股份（301602）、中银金融资产投资有限公司、中银资本私募基金管理（北京）有限公司、广东省产业发展投资基金合伙企业（有限合伙）、 粤财中垠私募股权投资基金管理（广东）有限公司、东莞松山湖产业投资母基金合伙企业（有限合伙）共同出资。据媒体报道，此前，超研股份发布公告 称，该基金投资方向将重点投向新型储能、生物医药、智能终端产业链及相关领域企业。 天眼一下 品 应用 ▼ | | 皇公司 在用的商业查询工具 | 童老板 商关系 音风险 | | | | --- | --- | --- | --- | --- | | | 家中小企业发展子基金旗下机构 | 广东粤财中瀛新兴产业股权投资基金合伙企业 (有限合 3 | 天眼一下 品 应用 ▼ | 商务合作 | | 基本信息 6 | 法律诉讼 | 经营风险 | 经营信息 公司发展 | ...

证券之星消息，科锐国际(300662)12月29日在投资者关系平台上答复投资者关心的问题。 投资者提问：你好，十五五规划强调"人力资源开发投资"与"专才外包"，公司灵活用工业务中技术研发 类岗位占比超60%，且聚焦新能源、AI等新兴产业，请问当前面向高端制造、生物医药等赛道的"专才 外包"收入增速如何？针对残疾人就业等合规服务领域，公司是否已组建专业团队，相关业务的订单储 备及盈利模型是否成型？ 科锐国际回复：尊敬的投资者您好，今年上半年，公司灵活用工业务持续领跑，营业收入同比增长 29.31%，其中技术研发类岗位作为公司岗位外包业务的重点布局方向，整体趋势显著增长，在册灵活 用工人员结构占比超70%，凸显公司在高附加值岗位的人才配置能力不断增强，形成核心竞争优势。感 谢您的关注！ 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

证券日报网讯12月29日，微光股份（002801）在互动平台回答投资者提问时表示，公司离心风机、EC 风机配套于相关洁净室设备，终端可应用于半导体、生物医药等多个领域，受产业链分工及产品最终使 用场景多样性影响，无法精准统计应用于半导体领域的具体营收情况。 ...

Core Viewpoint - Junshi Biosciences is positioned as a comprehensive innovative pharmaceutical company with capabilities spanning drug discovery, clinical research, large-scale production, and commercialization, aiming for a global footprint while being rooted in China [2] Group 1: Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020, focusing on the research and commercialization of monoclonal antibody drugs and other therapeutic proteins [7] - The company's main revenue sources include drug sales (90.67%), technology licensing and royalties (8.74%), and technical services (0.59%) [7] - As of September 30, 2023, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a year-on-year growth of 35.72% [8] Group 2: Product Pipeline and Innovations - The company has developed a robust product pipeline, including its core product, Toripalimab, which is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review [2] - Toripalimab is also the first innovative biopharmaceutical developed and produced in China to receive FDA approval, with approvals in multiple regions including the U.S., EU, and Australia [2] - Junshi Biosciences is advancing its self-developed Tifcemalimab, the world's first anti-BTLA monoclonal antibody entering clinical development, with two Phase III registration trials ongoing [2] Group 3: Collaborations and Future Developments - On October 27, 2023, Junshi Biosciences announced collaborations with several institutions, including Peking University and the Chinese Academy of Sciences, to develop a monkeypox recombinant protein vaccine [3] - The company’s subsidiary, JunTuo Biologics, is involved in the preclinical development of vaccines for monkeypox and Zika virus, indicating a focus on expanding its vaccine pipeline [3]

记者 辛圆 12月29日，财政部公布了2025年1-11月全国国有及国有控股企业经济运行情况。 数据显示，1-11月，全国国有及国有控股企业（以下称国有企业）营业总收入同比增长1.0%，涨幅较前10个月提升0.1个百分点。利润总额同比下降3.1%， 降幅较前10个月扩大0.1个百分点。 会议强调，2026年中央企业要全力以赴稳经营、提质效。拓市场方面，要探索运用各种大数据模型和行业模型，精准捕捉潜在市场需求，创新提升商品和服 务品质，培育壮大文旅、数字、健康等消费新场景，努力形成新的增长点。 对于2026年的投资工作，会议提出，要围绕产业链强基补短、基础设施建设、能源资源保障、前瞻产业布局等重点领域，用好各类支持政策，靠前谋划实施 一批重大项目和标志性工程，厚植可持续发展基础。 并购重组方面，会议提到，要大力推进战略性、专业化重组整合和高质量并购。平衡收益和风险，积极获取核心要素、培育竞争优势、抢占发展先机，国有 资本投资、运营公司要更好发挥平台作用。 《人民日报》近期刊发了对国资委主任张玉卓的专访。在推进国有经济布局优化方面，张玉卓提到，"十五五"期间，国资委将指导推动中央企业进一步聚焦 主责主业、发展实体 ...

据了解，梁溪科技城是一家植根无锡的产业园区综合服务运营商。公司秉持"服务赋能园区、创新驱动 产业"的使命，通过专业化运营和系统化管理，为园区企业提供全方位支持，持续助力区域产业升级与 经济高质量发展。 中小企业是推动创新、促进就业、改善民生的重要力量，也是金融服务实体经济的重要体现。本次债券 募集资金将用于置换和投资中小微企业的股权投资和基金投资，重点投向人工智能、低空经济、生物医 疗、航空航天等战略性新兴领域，旨在精准赋能科技型中小微企业，促进产业链创新链深度融合。 新华财经上海12月29日电（记者杨溢仁） 12月29日，由东吴证券承销的无锡市梁溪科技城园区发展集 团有限公司（以下简称"梁溪科技城"）2025年中小微企业支持可续期公司债券在上交所发行。 本期债券是江苏省首单中小微企业支持可续期公司债券，发行规模3.5亿元，募集资金用于支持中小微 企业发展。 作为本期债券的牵头主承销商，东吴证券的相关负责人表示，将充分发挥其在债券市场的专业优势与创 新能力，积极响应国家关于金融服务实体经济、支持中小微企业发展的政策导向，通过"中小微+可续 期"债权创新条款设计，充分发挥其在地方国企转型、创新金融产品等领域的专 ...

以下文章来源于清科研究 ，作者创造价值的 清科研究 . 清科研究中心致力于为众多的有限合伙人、VC/PE机构、战略投资者、以及政府机构、律师事务所、会 计事务所、投资银行、研究机构等提供专业的信息、数据、研究和咨询服务。 奖项语或运 2025年中国创业投资机构50强 评选标准 | 评分项目 | | 权重分布 | | --- | --- | --- | | 管理可投资中国的资本量 | | 5% | | 募资金额 | | 10% | | 投资 | 案例数量 | 15% | | 投资金额 | | 15% | | 退出 | IPO项目数量 | 10% | | IPO账面金额 | | 10% | | 现金退出总金额 | | 10% | | 全部退出案例综合回报 | (倍数和IRR) | 25% | 2025年中国行业细分投资机构榜单 NO 4 The 1 See 3 | | IT K = | | | --- | --- | --- | | | 评分项目 | 权重分布 | | 投资 | 投资该行业的案例数量 | 25% | | | 投资该行业的案例金额 | 25% | | | 投资该行业的占比 | 10% | | 退出 ...

[晨会纪要 Table_NewTitle] 20251229 [Table_Reportdate] 2025年12月29日 [证券分析师： Table_Authors] 吴骏燕 S0630517120001 wjyan@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 证券分析师： 刘思佳 S0630516080002 liusj@longone.com.cn 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.利润增速回落，但结构上仍有亮点——国内观察：2025年11月工业企业利润数据 ➢ 2.宏图新启，升维致远——2026年宏观经济及资产配置展望 ➢ 1.全国财政工作会议在北京召开 ➢ 2.2026年全国两会召开时间确定 ➢ 3.工信部：2026年要打造集成电路、新材料等新兴支柱产业 ➢ 4.国家创业投资引导基金正式启动 1.重点推荐 | 年 月工业企业利 1.1. 利润增速回落，但结构上仍有亮点——国 ...

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.06% on December 29, with a current price of 6.65 CNY per share and a market capitalization of 3.816 billion CNY [1] Group 1: Financial Performance - For the period from January to September 2025, TaiLong Pharmaceutical reported a revenue of 1.187 billion CNY, representing a year-on-year decrease of 11.47% [2] - The net profit attributable to the parent company for the same period was 25.3255 million CNY, down 12.36% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.5307 million CNY distributed over the last three years [3] Group 2: Stock Market Activity - The stock price of TaiLong Pharmaceutical has increased by 30.65% year-to-date, but has seen a decline of 5.41% over the last five trading days and 9.77% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on December 10, where it recorded a net buy of -8.4516 million CNY [1] - As of September 30, 2025, the number of shareholders decreased to 40,400, while the average circulating shares per person increased by 1.09% to 14,190 shares [2] Group 3: Business Overview - TaiLong Pharmaceutical, established on August 31, 1998, operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The company's revenue composition includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]